Literature DB >> 10527365

Guillain-Barré syndrome: rehabilitation outcome and recent developments.

E M Melillo1, J M Sethi, V Mohsenin.   

Abstract

Guillain-Barré syndrome is the most common polyneuropathy causing major disability and respiratory failure. Respiratory complications are the main cause of death. Improved respiratory care and new treatment strategies such as plasmaphoresis and immunoglobulin have been shown to improve outcome. We studied the course and outcome of 37 patients with Guillain-Barré syndrome who were admitted to a rehabilitation and respiratory care facility over a 10-year period. There were 21 males and 16 females with a mean age of 62+/-3 years. Fourteen patients developed respiratory failure requiring endotracheal intubation and mechanical ventilation. The mean duration of mechanical ventilation was 38+/-10 days. All patients were successfully liberated from the ventilator. However, 83 percent of the patients were moderately to severely disabled at the time of discharge. Thirteen out of 37 (35 percent) developed long-term disability. None of the patients died over the period of follow-up. These results indicate that early recognition and treatment of respiratory complications in Guillain-Barré syndrome could reduce the morbidity and mortality of this condition.

Entities:  

Mesh:

Year:  1998        PMID: 10527365      PMCID: PMC2578935     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  35 in total

Review 1.  Recurrent Guillain-Barré syndrome: lightning does strike twice.

Authors:  T A Roper; S M Alani
Journal:  Br J Hosp Med       Date:  1995 Apr 19-May 2

2.  Recovery in Landry-Guillain-Barré syndrome after prolonged respiratory support.

Authors:  A C Whitehouse; T L Petty
Journal:  Lancet       Date:  1969-05-24       Impact factor: 79.321

3.  Noninvasive ventilation. Does it work, for whom, and how?

Authors:  N S Hill
Journal:  Am Rev Respir Dis       Date:  1993-04

Review 4.  Guillain-Barré syndrome.

Authors:  R A Hughes; J H Rees
Journal:  Curr Opin Neurol       Date:  1994-10       Impact factor: 5.710

5.  Landry-Guillain-Barré syndrome presenting with symptoms of upper airway obstruction.

Authors:  A Larsen; J D Tobias
Journal:  Pediatr Emerg Care       Date:  1994-12       Impact factor: 1.454

6.  Delayed recovery from respiratory paralysis due to the Guillain-Barre syndrome.

Authors:  J P Knoedler; D E Niewoehner
Journal:  Chest       Date:  1981-07       Impact factor: 9.410

7.  Impaired ventilatory capacity after recovery from Guillain-Barré syndrome.

Authors:  K S Sibert; R N Sladen
Journal:  J Clin Anesth       Date:  1994 Mar-Apr       Impact factor: 9.452

8.  Ventilatory drive and carbon dioxide response in ventilatory failure due to myasthenia gravis and Guillain-Barré syndrome.

Authors:  C O Borel; J S Teitelbaum; D F Hanley
Journal:  Crit Care Med       Date:  1993-11       Impact factor: 7.598

Review 9.  Intensive management and treatment of severe Guillain-Barré syndrome.

Authors:  E F Hund; C O Borel; D R Cornblath; D F Hanley; G M McKhann
Journal:  Crit Care Med       Date:  1993-03       Impact factor: 7.598

Review 10.  Respiratory dysfunction in Guillain-Barré syndrome.

Authors:  J S Teitelbaum; C O Borel
Journal:  Clin Chest Med       Date:  1994-12       Impact factor: 2.878

View more
  3 in total

1.  Long-term outcome of Guillain-Barré syndrome.

Authors:  S Koeppen; K Kraywinkel; T E Wessendorf; C E Ehrenfeld; M Schürks; H C Diener; C Weimar
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

2.  Coexisting infectious diseases on admission as a risk factor for mechanical ventilation in patients with Guillain-Barré syndrome.

Authors:  Shinichiro Kobori; Tatsuhiko Kubo; Makoto Otani; Keiji Muramatsu; Yoshihisa Fujino; Hiroaki Adachi; Hiromasa Horiguchi; Kiyohide Fushimi; Shinya Matsuda
Journal:  J Epidemiol       Date:  2017-03-07       Impact factor: 3.211

3.  Risk factors for the severity of Guillain-Barré syndrome and predictors of short-term prognosis of severe Guillain-Barré syndrome.

Authors:  Puyuan Wen; Lisha Wang; Hong Liu; Li Gong; Han Ji; Hongliang Wu; Wenzheng Chu
Journal:  Sci Rep       Date:  2021-06-02       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.